Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines

Oncology Nursing Forum

Volumn 33, Issue 3, 2006, Pages 535-542

  Wood, Lisa J ^a   Nail, Lillian M ^a   Gilster, April ^a   Winters, Kerri A ^a   Elsea, Collin R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746196786     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/06.ONF.535-542     Document Type: Review

References (98)

1. Ancoli-Israel, S., Moore, P.J., & Jones, V. (2001). The relationship between fatigue and sleep in cancer patients: A review. European Journal of Cancer Care, 10, 245-255.
2. Anderson, K.O., Getto, C.J., Mendoza, T.R., Palmer, S.N., Wang, X.S., Reyes-Gibby, C.C., et al. (2003). Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. Journal of Pain and Symptom Management, 25, 307-318.
3. Anisman, H., Merali, Z., Poulter, M.O., & Hayley, S. (2005). Cytokines as a precipitant of depressive illness: Animal and human studies. Current Pharmaceutical Design, 11, 963-972.
4. Argiles, J.M., Busquets, S., & Lopez-Soriano, F.J. (2005). The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 37, 2036-2046.
5. Badger, A.M., Bradbeer, J.N., Votta, B., Lee, J.C., Adams, J.L., & Griswold, D.E. (1996). Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. Journal of Pharmacology and Experimental Therapeutics, 279, 1453-1461.
6. Berger, A.M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25, 51-62.
7. Berger, A.M., & Farr, L. (1999). The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncology Nursing Forum, 26, 1663-1671.
8. Berger, A.M., & Higginbotham, P. (2000). Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum, 27, 1443-1448.
9. Berger, A.M., VonEssen, S., Kuhn, B.R., Piper, B.F., Agrawal, S., Lynch, J.C., et al. (2003). Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: Results of a feasibility intervention study. Oncology Nursing Forum, 30, 513-522.
10. Bernard, S., Gill, P., Rosen, P., Gavigan, M., Steagall, A., Ellingham, E., et al. (1991). A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Medical and Pediatric Oncology, 19, 276-282.
11. Bluthe, R.M., Laye, S., Michaud, B., Combe, C., Dantzer, R.. & Parnet, P. (2000). Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: A study with interleukin-1 type I receptor-deficient mice. European Journal of Neuroscience, 12, 4447-4456.
12. Bluthe, R.M., Michaud, B., Poli, V., & Dantzer, R. (2000). Role of IL-6 in cytokine-induced sickness behavior: A study with IL-6 deficient mice. Physiology and Behavior, 70, 367-373.
13. Bogdan, C., & Ding, A. (1992). Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. Journal of Leukocyte Biology, 52, 119-121.
14. Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C.L., Gupta, A., et al. (2002). Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Journal of Immunology, 168, 4070-4077.
15. Cahlin, C., Korner, A., Axelsson, H., Wang, W., Lundholm, K., & Svanberg, E. (2000). Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Research, 60, 5488-5493.
16. Capuron, L., Ravaud, A., Miller, A.H., & Dantzer, R. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain, Behavior, and Immunity, 18, 205-213.
17. Carpenter, J.S., Elam, J.L., Ridner, S.H., Carney, P.H., Cherry, G.J., & Cucullu, H.L. (2004). Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncology Nursing Forum, 31, 591-598.
18. Chao, C.C., DeLaHunt, M., Hu, S., Close, K., & Peterson, P.K. (1992). Immunologically mediated fatigue: A murine model. Clinical Immunology and Immunopathology, 64, 161-165.
19. Curt, G.A., Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist, 5, 353-360.
20. Dantzer, R. (2004a). Cytokine-induced sickness behaviour: A neuroimmune response to activation of innate immunity. European Journal of Pharmacology, 500, 399-411.
21. Dantzer, R. (2004b). Innate immunity at the forefront of psychoneuroimmunology. Brain, Behavior, and Immunity, 18, 1-6.
22. Dantzer, R., Aubert, A., Bluthe, R.M., Gheusi, G., Cremona, S., Laye, S., et al. (1999). Mechanisms of the behavioural effects of cytokines. Advances in Experimental Medicine and Biology, 461, 83-105.
23. Davidson, J.R., MacLean, A.W., Brundage, M.D., & Schulze, K. (2002). Sleep disturbance in cancer patients. Social Science and Medicine, 54, 1309-1321.
24. Ding, A.H., Porteu, F., Sanchez, E., & Nathan, C.F. (1990). Shared actions of endotoxin and Taxol on TNF receptors and TNF release. Science, 248, 370-372.
25. Dropcho, E.J. (2004). Neurotoxicity of cancer chemotherapy. Seminars in Neurology, 24, 419-426.
26. Elsea, C.R., Nail, L.M., Druker, B.J., & Wood, L.J. (2006). Induction of IL-1β, TNF-α, and IL-6 production by mechanistically distinct cancer chemotherapy drugs in macrophages: The role of p38 MAPK & JNK. Unpublished manuscript.
27. Enomoto, A., Rho, M.C., Fukami, A., Hiraku, O., Komiyama, K., & Hayashi, M. (2004). Suppression of cancer cachexia by 20S, 21-epoxy- resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochemical and Biophysical Research Communications, 323, 1096-1102.
28. Ferrell, B.R., Grant, M., Funk, B., Garcia, N., Otis-Green, S., & Schaffner, M.L. (1996). Quality of life in breast cancer. Cancer Practice, 4, 331-340.
29. Glaus, A. (1998). Fatigue in patients with cancer. Analysis and assessment. Recent Results in Cancer Research. 145, I-XI, 1-172.
30. Goldblatt, F., & Isenberg, D.A. (2005). New therapies for rheumatoid arthritis. Clinical and Experimental Immunology, 140, 195-204.
31. Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
32. Haldar, S., Basu, A., & Croce, C.M. (1997). Bcl2 is the guardian of microtubule integrity. Cancer Research, 57, 229-233.
33. Hentze, M.W., Muckenthaler, M.U., & Andrews, N.C. (2004). Balancing acts: Molecular control of mammalian iron metabolism. Cell, 117, 285-297.
34. Hill, A.G., Siegel, J., Rounds, J., & Wilmore, D.W. (1997). Metabolic responses to interleukin-1: Centrally and peripherally mediated. Annals of Surgery, 225, 246-251.
35. Jelkmann, W., Pagel, H., Wolff, M., & Fandrey, J. (1992). Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sciences, 50, 301-308.
36. Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005). Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 106, 1864-1866.
37. Kent, S., Bret-Dibat, J.L., Kelley, K.W., & Dantzer, R. (1996). Mechanisms of sickness-induced decreases in food-motivated behavior. Neuroscience and Biobehavioral Reviews, 20(1), 171-175.
38. Knight, K., Wade, S., & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer. A systematic review of the literature. American Journal of Medicine, 116(Suppl. 7A), 11S-26S.
39. Kozak, W., Kluger, M.J., Soszynski, D., Conn, C.A., Rudolph, K., Leon, L.R., et al. (1998). IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Annals of the New York Academy of Sciences, 856, 33-47.
40. Krueger, J.M., & Majde, J.A. (1994). Microbial products and cytokines in sleep and fever regulation. Critical Reviews in Immunology, 14, 355-379.
41. Krueger, J.M., Obal, F.J., Fang, J., Kubota, T., & Taishi, P. (2001). The role of cytokines in physiological sleep regulation. Annals of the New York Academy of Sciences, 933, 211-221.
42. Laviano, A., Cangiano, C., Fava, A., Muscaritoli, M., Mulieri, G., & Rossi Fanelli, F. (1999). Peripherally injected IL-1 induces anorexia and increases brain tryptophan concentrations. Advances in Experimental Medicine and Biology, 467, 105-108.
43. Lee, B.N., Dantzer, R., Langley, K.E., Bennett, G.J., Dougherty, P.M., Dunn, A.J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11, 279-292.
44. Lee, K., Cho, M., Miaskowski, C., & Dodd, M. (2004). Impaired sleep and rhythms in persons with cancer. Sleep Medicine Reviews, 8, 199-212.
45. Lee, K.A. (2001). Sleep and fatigue. Annual Review of Nursing Research, 19, 249-273.
46. Lyczak, J.B. (2004). Innate immunity. In G.B. Pier, J.B. Lyczak, & M. Wetzler (Eds.), Immunology, infection, and immunity. Washington, DC: ASM Press.
47. Macdougall, I.C., & Cooper, A.C. (2002). Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrology, Dialysis, and Transplantation, 17(Suppl. 11), 39-43.
48. McCarthy, D.O. (2000). Tumor necrosis factor alpha and interleukin-6 have differential effects on food intake and gastric emptying in fasted rats. Research in Nursing Health, 23, 222-228.
49. Means, R.T. (2004). Hepcidin and cytokines in anaemia. Hematology, 9, 357-362.
50. Mercadante, S., Gebbia, V., Marrazzo, A., & Filosto, S. (2000). Anaemia in cancer: Pathophysiology and treatment. Cancer Treatment Reviews, 26, 303-311.
51. Mercadante, S., Girelli, D., & Casuccio, A. (2004). Sleep disorders in advanced cancer patients: Prevalence and factors associated. Supportive Care in Cancer, 12, 355-359.
52. Mock, V., Atkinson, A., Barsevick, A., Cella, D., Cimprich, B., Cleeland, C., et al. (2003). Cancer-related fatigue clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 1, 308-331.
53. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., et al. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine, 344, 961-966.
54. Nail, L.M., & Winningham, M.L. (1995). Fatigue and weakness in cancer patients: The symptoms experience. Seminars in Oncology Nursing, 11, 272-278.
55. Nakamura, Y., Shimizu, H., Nishijima, C., Ueno, M., & Arakawa, Y. (2001). Delayed functional recovery by vincristine after sciatic nerve crush injury: A mouse model of vincristine neurotoxicity. Neuroscience Letters, 304(1-2), 5-8.
56. Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., et al. (2005). Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 106, 2627-2632.
57. Ocean, A.J., & Vahdat, L.T. (2004). Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12, 619-625.
58. Ogawa, T., Mimura, Y., Isowa, K., Kato, H., Mitsuishi, M., Toyoshi, T., et al. (2001). An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicology Letters, 121(2), 97-106.
59. Okereke, O.I. (2002). Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. Psychosomatics, 43, 237-240.
60. Olson, J.M., & Hallahan, A.R. (2004). p38 MAP kinase: A convergence point in cancer therapy. Trends in Molecular Medicine, 10, 125-129.
61. Olson, K., Tom, B., Hewitt, J., Whittingham, J., Buchanan, L., & Ganton, G. (2002). Evolving routines: Preventing fatigue associated with lung and colorectal cancer. Qualitative Health Research, 12, 655-670.
62. Omdal, R., & Gunnarsson, R. (2004). The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis-A pilot study. Rheumatology International, 25, 481-484.
63. Ottenweller, J.E., Natelson, B.H., Gause, W.C., Carroll, K.K., Beldowicz, D., Zhou, X.D., et al. (1998). Mouse running activity is lowered by Brucella abortus treatment: A potential model to study chronic fatigue. Physiology and Behavior, 63, 795-801.
64. Ozturk, G., Erdogan, E., Anlar, O., Kosem, M., & Taspinar, M. (2005). Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine, 29, 31-41.
65. Pasparakis, M., Alexopoulou, L., Episkopou, V., & Kollias, G. (1996). Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. Journal of Experimental Medicine, 184, 1397-1411.
66. Piper, B.F. (1990). Piper Fatigue Scale available for clinical testing. Oncology Nursing Forum, 17, 661-662.
67. Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., et al. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO Journal, 13, 1189-1196.
68. Polomano, R.C., Mannes, A.J., Clark, U.S., & Bennett, G.J. (2001). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain, 94, 293-304.
69. Purswani, M.U., Eckert, S.J., Arora, U.K., & Noel, G.J. (2002). Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. Journal of Antimicrobial Chemotherapy, 50, 51-58.
70. Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., et al. (2004). Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 25, 94-102.
71. Roux, P.P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68, 320-344.
72. Schaefer, M., Horn, M., Schmidt, F., Schmid-Wendtner, M.H., Volkenandt, M., Ackenheil, M., et al. (2004). Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain, Behavior, and Immunity, 18, 555-562.
73. Schaefer, M., Schmidt, F., Horn, M., Schmid-Wendtner, M.H., & Volkenandt, M. (2004). Depression during treatment with interferon alpha. Psychosomatics, 45, 176.
74. Scheibel, R.S., Valentine, A.D., O'Brien, S., & Meyers, C.A. (2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. Journal of Neuropsychiatry and Clinical Neuroscience, 16, 185-191.
75. Schwartz, A.L. (2000). Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Practice, 8, 16-24.
76. Schwartz, A.L., Nail, L.M., Chen, S., Meek, P., Barsevick, A.M., King, M.E., et al. (2000). Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Investigations, 18, 11-19.
77. Segreti, J., Gheusi, G., Dantzer, R., Kelley, K.W., & Johnson, R.W. (1997). Defect in interleukin-1beta secretion prevents sickness behavior in C3H/ HeJ mice. Physiology and Behavior, 61, 873-878.
78. Sheng, W.S., Hu, S., Ding, J.M., Chao, C.C., & Peterson, P.K. (2001). Cytokine expression in the mouse brain in response to immune activation by Corynebacterium parvum. Clinical and Diagnostic Laboratory Immunology. 8, 446-448.
79. Sheng, W.S., Hu, S., Lamkin, A., Peterson, P.K., & Chao, C.C. (1996). Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clinical Immunology and Immunopathology, 81, 161-167.
80. Sommer, C., & Kress, M. (2004). Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuroscience Letters, 361(1-3), 184-187.
81. ten Tije, A.J., Smorenburg, C.H., Seynaeve, C., Sparreboom, A., Schothorst, K.L., Kerkhofs, L.G., et al. (2004). Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. European Journal of Cancer, 40, 352-357.
82. Testa, U. (2004). Apoptotic mechanisms in the control of erythropoiesis. Leukemia, 18, 1176-1199.
83. Thomas, A.J., Davis, S., Morris, C., Jackson, E., Harrison, R., & O'Brien, J.T. (2005). Increase in interleukin-1beta in late-life depression. American Journal of Psychiatry, 162, 175-177.
84. Tisdale, M.J. (2004). Cancer cachexia. Langenbeck's Archives of Surgery, 389, 299-305.
85. Trask, P.C., Paterson, A.G., Esper, P., Pau, J., & Redman, B. (2004). Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psycho-Oncology, 13, 526-536.
86. Tuglu, C., Kara, S.H., Caliyurt, O., Vardar, E., & Abay, E. (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology, 170, 429-433.
87. Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Kales, A., Tyson, K., & Chrousos, G.P. (1997). Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. Journal of Clinical Endocrinology and Metabolism, 82, 1313-1316.
88. Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Lotsikas, A., Zachman, K., Kales, A., et al. (1999). Orcadian interleukin-6 secretion and quantity and depth of sleep. Journal of Clinical Endocrinology and Metabolism, 84, 2603-2607.
89. Vgontzas, A.N., Zoumakis, E., Bixler, E.O., Lin, H.M., Follett, H., Kales, A., et al. (2004). Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. Journal of Clinical Endocrinology and Metabolism, 89, 2119-2126.
90. Vogelzang, N.J., Breitbart, W., Cella, D., Curt, G.A., Groopman, J.E., Horning, S.J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Seminars in Hematology, 34(3, Suppl. 2), 4-12.
91. Waterston, A., & Bower, M. (2004). Fifty years of multicentric Castleman's disease. Acta Oncologica, 43, 698-704.
92. Watkins, L.R., Goehler, L.E., Relton, J., Brewer, M.T., & Maier, S.F. (1995). Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Research, 692, 244-250.
93. Weinblatt, M.E., Keystone, E.G., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism, 48, 35-45.
94. Winningham, M.L., Nail, L.M., Burke, M.B., Brophy, L., Cimprich, B., Jones, L.S., et al. (1994). Fatigue and the cancer experience: The state of the knowledge. Oncology Nursing Forum, 21, 23-36.
95. Wood, L.J., Nail, L.M., Perrin, N.A., Elsea, C.R., Fischer, A., & Druker, B.J. (in press). The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Biological Research for Nursing, 7(4).
96. Woolf, C.J., Allchorne, A., Safieh-Garabedian, B., & Poole, S. (1997). Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha. British Journal of Pharmacology, 121, 417-424.
97. Zaki, M.H., Nemeth, J.A., & Trikha, M. (2004). CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. International Journal of Cancer, 111, 592-595.
98. Zhong, J., Dietzel, I.D., Wahle, P., Kopf, M., & Heumann, R. (1999). Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. Journal of Neuroscience, 19, 4305-4313.